The ministry has developed a rapid review process for truly innovative drugs. This means that the ministry begins the funding review process in Ontario prior to the drug receiving federal approval for sale in Canada (i.e. receipt of Notice of Compliance [NOC]). The ministry is setting a benchmark that funding decisions will be made by the committee within 30 days following the drug product's receipt of NOC.

Highlights

• Since October 2006, 15 drugs/indications have been submitted for rapid review and six have been accepted for rapid review.
• The ministry's commitment to this process is evident. The rapid review process is authorized pursuant to the regulation under the Ontario Drug Benefit Act (ODBA). These provisions are found in section 12 (1) (a) (ii) of O. Reg. 201/96 under ODBA.

Guidelines for Rapid Review Submissions  [PDF]

See also :

• Exceptional Access and Conditional Listings Progress
• Aligning Funding Policies